Match!
Breast Cancer Research
IF
5.68
Papers
4639
Papers 4684
1 page of 469 pages (4,684 results)
Newest
#1Camille Lehuédé (University of Toulouse)H-Index: 3
#2Xia Li (University of Toulouse)H-Index: 1
Last.Sophie Le Gonidec (University of Toulouse)H-Index: 1
view all 17 authors...
Introduction Clinical studies suggest that obesity, in addition to promoting breast cancer aggressiveness, is associated with a decrease in chemotherapy efficacy, although the mechanisms involved remain elusive. As chemotherapy is one of the main treatments for aggressive or metastatic breast cancer, we investigated whether adipocytes can mediate resistance to doxorubicin (DOX), one of the main drugs used to treat breast cancer, and the mechanisms associated.
#1C Van Berckelaer (University of Antwerp)H-Index: 1
#2C Rypens (University of Antwerp)H-Index: 1
Last.Peter B. Vermeulen (University of Antwerp)H-Index: 29
view all 13 authors...
Background Inflammatory breast cancer (IBC) is a rare and rapidly progressive form of invasive breast cancer. The aim of this study was to explore the clinical evolution, stromal tumour-infiltrating lymphocytes (sTIL) infiltration and programmed death-ligand 1 (PD-L1) expression in a large IBC cohort.
#1Abdi Ghaffari (Queen's University)H-Index: 3
#2Victoria Hoskin (Queen's University)H-Index: 3
Last.Yolanda Madarnas (Queen's University)H-Index: 7
view all 12 authors...
Background Limited understanding of the cancer biology of metastatic sites is a major factor contributing to poor outcomes in cancer patients. The regional lymph nodes are the most common site of metastasis in most solid cancers and their involvement is a strong predictor of relapse in breast cancer (BC). We have previously shown that ezrin, a cytoskeletal–membrane linker protein, is associated with lymphovascular invasion and promotes metastatic progression in BC. However, the efficacy of pharm...
#1Tess V. Clendenen (NYU: New York University)H-Index: 15
#2Wenzhen Ge (NYU: New York University)H-Index: 5
Last.A. Heather Eliassen (Harvard University)H-Index: 37
view all 24 authors...
Background Models that accurately predict risk of breast cancer are needed to help younger women make decisions about when to begin screening. Premenopausal concentrations of circulating anti-Mullerian hormone (AMH), a biomarker of ovarian reserve, and testosterone have been positively associated with breast cancer risk in prospective studies. We assessed whether adding AMH and/or testosterone to the Gail model improves its prediction performance for women aged 35–50.
#1Youdinghuan ChenH-Index: 2
#2Yue WangH-Index: 2
Last.Brock C. Christensen (Dartmouth–Hitchcock Medical Center)H-Index: 2
view all 9 authors...
Background BRCA1-mutated cancers exhibit deficient homologous recombination (HR) DNA repair, resulting in extensive copy number alterations and genome instability. HR deficiency can also arise in tumors without a BRCA1 mutation. Compared with other breast tumors, HR-deficient, BRCA1-like tumors exhibit worse prognosis but selective chemotherapeutic sensitivity. Presently, patients with triple negative breast cancer (TNBC) who do not respond to hormone endocrine-targeting therapy are given cytoto...
#1Aadya NagpalH-Index: 1
#2Richard P. Redvers (La Trobe University)H-Index: 10
Last.Steven David (Peter MacCallum Cancer Centre)H-Index: 3
view all 0 authors...
Background Human epidermal growth factor receptor-2 (HER2)-targeted therapies prolong survival in HER2-positive breast cancer patients. Benefit stems primarily from improved control of systemic disease, but up to 50% of patients progress to incurable brain metastases due to acquired resistance and/or limited permeability of inhibitors across the blood-brain barrier. Neratinib, a potent irreversible pan-tyrosine kinase inhibitor, prolongs disease-free survival in the extended adjuvant setting, an...
#1Stephen Chia (UBC: University of British Columbia)H-Index: 43
#2Miguel Mart ´ in (Complutense University of Madrid)H-Index: 47
Last.Janine Mansi ('KCL': King's College London)H-Index: 30
view all 26 authors...
Background Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disease-free survival (iDFS) in women who completed trastuzumab-based adjuvant therapy for early breast cancer (EBC). We assessed the prognostic and predictive significance of PIK3CA alterations in patients in ExteNET.
#1Hye Yeon Choi (Konkuk University)H-Index: 12
#2Gwang Mo Yang (Konkuk University)H-Index: 1
Last.Kyung Mi Lee (KU: Korea University)H-Index: 31
view all 11 authors...
Background Epithelial-mesenchymal transition (EMT) occurs in the tumor microenvironment and presents an important mechanism of tumor cell intravasation, stemness acquisition, and metastasis. During metastasis, tumor cells enter the circulation to gain access to distant tissues, but how this fluid microenvironment influences cancer cell biology is poorly understood.
#1Kevin D. Wright (MCW: Medical College of Wisconsin)H-Index: 3
#2Bradley Miller (MCW: Medical College of Wisconsin)H-Index: 6
Last.Hallgeir Rui (MCW: Medical College of Wisconsin)H-Index: 44
view all 12 authors...
Background SHC1 proteins (also called SHCA) exist in three functionally distinct isoforms (p46SHC, p52SHC, and p66SHC) that serve as intracellular adaptors for several key signaling pathways in breast cancer. Despite the broad evidence implicating SHC1 gene products as a central mediator of breast cancer, testing the isoform-specific roles of SHC1 proteins have been inaccessible due to the lack of isoform-specific inhibitors or gene knockout models.
#1Rachel A. Sabol (Tulane University)H-Index: 1
#2Annie C. Bowles (Tulane University)H-Index: 9
Last.Lucio Miele (LSU: Louisiana State University)H-Index: 64
view all 13 authors...
Background Breast cancer is the second leading cause of cancer deaths in the USA. Triple-negative breast cancer (TNBC) is a clinically aggressive subtype of breast cancer with high rates of metastasis, tumor recurrence, and resistance to therapeutics. Obesity, defined by a high body mass index (BMI), is an established risk factor for breast cancer. Women with a high BMI have increased incidence and mortality of breast cancer; however, the mechanisms(s) by which obesity promotes tumor progression...
12345678910